Crossmark

Mutagenic and carcinogenic potency determinations for NDMA support the cumulative dose assumption underpinning the less-than-lifetime Threshold of Toxicological Concern

Crossref DOI link: https://doi.org/10.1007/s00204-026-04385-0

Published Online: 2026-04-14

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wills, John W. https://orcid.org/0000-0002-4347-5394
White, Angela

Harte, Danielle S. G.

Buckley, Ruby

Harvey, James S.

Lynch, Anthony M.
License Information

Text and Data Mining valid from 2026-04-14

Version of Record valid from 2026-04-14
More Information

Article History

Received: 27 January 2026

Accepted: 19 March 2026

First Online: 14 April 2026

Declarations

:

: JWW, AW, DSGH, RB, RH and AML are employees of GlaxoSmithKline.

: All dose–response data unpinning the analyses presented in this manuscript were collected from previously-published literature.

Document is current

Any future updates will be listed below